Following the modification and introduction of legislation governing the safety, development and use of regenerative and cell therapies in Japan in late 2014, companies in the space have been generally positive on the shape and impact of the supportive regulatory environment in the country – which has already led to the reimbursement and launch of several therapies.
Tokyo-based Healios K.K. is one such company. Formed in 2011 as Retina Institute Japan, a Fukuoka-based venture under Riken...